Skip to main content

Advertisement

SpringerLink
Log in

Pituitary tumors

  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Opinion statement

Pituitary adenomas are the most common intrasellar tumors. With the exception of prolactinomas, first-line treatment is almost always surgical. Prolactinomas are usually treated with dopamine agonists such as cabergoline or bromocriptine. Somatostatin analogues, such as octreotide and lanreotide, can be adjunctive to surgical therapy in acromegaly, although they can be used as primary therapy in selected cases. Pegvisomant, a growth hormone receptor antagonist, is reserved for acromegalic patients who are resistant to treatment with somatostatin analogues. No effective medical therapy is available for adenomas that secrete adrenocorticotropic hormone, and occasionally bilateral adrenalectomy is required to resolve severe hypercortisolemia. Radiation therapy (fractionated or radiosurgery) can be used for residual or recurrent pituitary tumors. Asymptomatic, nonfunctioning pituitary adenomas may be followed without any intervention, but surgery is typically indicated if there are symptoms of mass effect on the optic chiasm or endocrine dysfunction. In the hands of an experienced pituitary neurosurgeon, the prognosis for endocrinologic recovery and visual improvement is good.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Saeger W, Lüdecke DK, Buchfelder M, et al.: Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry [review]. Eur J Endocrinol 2007, 156:203–216.

    Article  PubMed  CAS  Google Scholar 

  2. Ezzat S, Asa SL, Couldwell WT, et al.: The prevalence of pituitary adenomas: a systematic review. Cancer 2004, 101:613–619.

    Article  PubMed  Google Scholar 

  3. Dekkers OM, Pereira AM, Romijn JA: Treatment and follow-up of clinically nonfunctioning pituitary macroadenomas. J Clin Endocrinol Metab 2008, 93:3717–3726.

    Article  PubMed  CAS  Google Scholar 

  4. Melmed S: Update in pituitary disease [review]. J Clin Endocrinol Metab 2008, 93:331–338.

    Article  PubMed  CAS  Google Scholar 

  5. Gueorguiev M, Grossman AB: Pituitary gland and betacatenin signaling: from ontogeny to oncogenesis. Pituitary 2008 Oct 23 (Epub ahead of print).

  6. Tsukada T, Nagamura Y, Ohkura N: MEN1 gene and its mutations: basic and clinical implications. Cancer Sci 2008, 100:209–215.

    Article  CAS  Google Scholar 

  7. Keil MF, Stratakis CA: Pituitary tumors in childhood: update of diagnosis, treatment and molecular genetics. Expert Rev Neurother 2008, 8:563–574.

    Article  PubMed  CAS  Google Scholar 

  8. Mamelak AN, Carmichael JD, Park P, et al.: Atypical pituitary adenoma with malignant features. Pituitary 2008 Oct 24 (Epub ahead of print).

  9. Scheithauer BW, Gaffey TA, Lloyd RV, et al.: Pathobiology of pituitary adenomas and carcinomas. Neurosurgery 2006, 59:341–353.

    Article  PubMed  Google Scholar 

  10. Widhalm G, Wolfsberger S, Preusser M, et al.: Residual nonfunctioning pituitary adenomas: prognostic value of MIB-1 labeling index for tumor progression. J Neurosurg 2008 Nov 7 (Epub ahead of print).

  11. Moreno-Perez O, Peiro FM, Lopez P, et al.: An isolated pituitary metastasis as presentation of differentiated hepatocellular carcinoma mimicking a nonfunctioning macroadenoma. J Endocrinol Invest 2007, 30:428–433.

    PubMed  CAS  Google Scholar 

  12. Komninos J, Vlarsopoulou V, Protopara D, et al.: Tumors metastatic to the pituitary gland: case report and literature review. J Clin Endocrinol Metab 2007, 89:574–580.

    Article  CAS  Google Scholar 

  13. Ferrante E, Ferraroni M, Castrignano T, et al.: Non-functioning pituitary adenoma database: a useful resource to improve the clinical management of pituitary tumors. Eur J Endocrinol 2006, 155:823–829.

    Article  PubMed  CAS  Google Scholar 

  14. Vance ML: Pituitary adenoma: a clinician’s perspective. Endocr Pract 2008, 14:757–763.

    PubMed  Google Scholar 

  15. Gondim JA, de Almeida JP, de Albuquerque LA, et al.: Headache associated with pituitary tumors. J Headache Pain 2009, 10:15–20.

    Article  PubMed  Google Scholar 

  16. Nawar RN, AbdelMannan D, Selman WR, Arafah BM: Pituitary tumor apoplexy: a review. J Intensive Care Med 2008, 23:75–90.

    Article  PubMed  Google Scholar 

  17. Ben-Shlomo A, Melmed S: Acromegaly. Endocrinol Metab Clin North Am 2008, 37:101–122, viii.

    Article  PubMed  CAS  Google Scholar 

  18. Elamin MB, Murad MH, Mullan R, et al.: Accuracy of diagnostic tests for Cushing’s syndrome: a systematic review and metaanalyses. J Clin Endocrinol Metab 2008, 93:1553–1562.

    Article  PubMed  CAS  Google Scholar 

  19. Keogh BP: Recent advances in neuroendocrine imaging [review]. Curr Opin Endocrinol Diabetes Obes 2008, 15:371–375.

    PubMed  Google Scholar 

  20. Colao A, Di Somma C, Pivonello R, et al.: Medical therapy for clinically non-functioning pituitary adenomas. Endocr Relat Cancer 2008, 15:905–915.

    Article  PubMed  CAS  Google Scholar 

  21. Gillam MP, Molitch ME, Lombardi G, Colao A: Advances in the treatment of prolactinomas. Endocr Rev 2006, 27:485–534.

    Article  PubMed  CAS  Google Scholar 

  22. Mancini T, Casanueva FF, Giustina A: Hyperprolactinemia and prolactinomas. Endocrinol Metab Clin North Am 2008, 37:67–99, viii.

    Article  PubMed  CAS  Google Scholar 

  23. Ono M, Miki N, Kawamata T, et al.: Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. J Clin Endocrinol Metab 2008, 93:4721–4727.

    Article  PubMed  CAS  Google Scholar 

  24. Colao A, Pivonello R, Di Somma C, et al.: Medical therapy of pituitary adenomas: effects on tumor shrinkage. Rev Endocr Metab Disord 2008 Sep 13 (Epub ahead of print).

  25. Rasmussen VG, Poulsen SH, Dupont E, et al.: Heart valve disease associated with treatment with ergot-derived dopamine agonists: a clinical and echocardiographic study of patients with Parkinson’s disease. J Intern Med 2008, 263:90–98.

    PubMed  CAS  Google Scholar 

  26. Antonini A, Poewe W: Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson’s disease. Lancet Neurol 2007, 6:826–829.

    Article  PubMed  CAS  Google Scholar 

  27. Kars M, Pereira AM, Bax JJ, Romijn JA: Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required [review]. Eur J Endocrinol 2008, 159:363–367.

    Article  PubMed  CAS  Google Scholar 

  28. Devin JK, Lakhani VT, Byrd BF 3rd, Blevins LS Jr: Prevalence of valvular heart disease in a cohort of patients taking cabergoline for management of hyperprolactinemia. Endocr Pract 2008, 14:672–677.

    PubMed  Google Scholar 

  29. Lancellotti P, Livadariu E, Markov M, et al.: Cabergoline and the risk of valvular lesions in endocrine disease. Eur J Endocrinol 2008, 159:1–5.

    Article  PubMed  CAS  Google Scholar 

  30. Bogazzi F, Buralli S, Manetti L, et al.: Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia. Int J Clin Pract 2008, 62:1864–1869.

    Article  PubMed  CAS  Google Scholar 

  31. Vallette S, Serri K, Rivera J, et al.: Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary 2008 Jul 2 (Epub ahead of print).

  32. Wakil A, Rigby A, Clark A, Atkin S: Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease. Eur J Endocrinol 2008, 159:R11–R14.

    Article  PubMed  CAS  Google Scholar 

  33. Colao A, Galderisi M, Di Sarno A, et al.: Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. J Clin Endocrinol Metab 2008, 93:3777–3784.

    Article  PubMed  CAS  Google Scholar 

  34. Kars M, Delgado V, Holman VR, et al.: Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. J Clin Endocrinol Metab 2008, 93:3348–3356.

    Article  PubMed  CAS  Google Scholar 

  35. Molitch ME: The cabergoline-resistant prolactinoma patient: new challenges. J Clin Endocrinol Metab 2008, 93:4643–4645.

    Article  PubMed  CAS  Google Scholar 

  36. Carlsen SM, Lund-Johansen M, Schreiner T, et al.; on behalf of the Preoperative Octreotide Treatment of Acromegaly study group: Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial. J Clin Endocrinol Metab 2008, 93:2984–2990.

    Article  PubMed  CAS  Google Scholar 

  37. Chanson P, Salenave S: Acromegaly [review]. Orphanet J Rare Dis 2008, 3:17.

    Article  PubMed  Google Scholar 

  38. Attanasio R, Lanzi R, Losa M, et al.: Effects of lanreotide Autogel on growth hormone, insulinlike growth factor 1, and tumor size in acromegaly: a 1-year prospective multicenter study. Endocr Pract 2008, 14:846–855.

    PubMed  Google Scholar 

  39. Colao A, Pivonello R, Auriemma RS, et al.: Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur J Endocrinol 2006, 154:467–477.

    Article  PubMed  CAS  Google Scholar 

  40. Neggers SJ, de Herder WW, Janssen JA, et al.: Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety up to 4.5 years (median 2.2 years) of follow-up in 86 patients. Eur J Endocrinol 2009, 160:529–533.

    Article  PubMed  CAS  Google Scholar 

  41. Beck-Peccoz P, Persani L: Thyrotropinomas. Endocrinol Metab Clin North Am 2008, 37:123–134, viii–ix.

    Article  PubMed  CAS  Google Scholar 

  42. Chandler WF, Barkan AL: Treatment of pituitary tumors: a surgical perspective [review]. Endocrinol Metab Clin North Am 2008, 37:51–66, viii.

    Article  PubMed  Google Scholar 

  43. Porterfield JR, Thompson GB, Young WF Jr, et al.: Surgery for Cushing’s syndrome: an historical review and recent ten-year experience. World J Surg 2008, 32:659–677.

    Article  PubMed  Google Scholar 

  44. Prevedello DM, Pouratian N, Sherman J, et al.: Management of Cushing’s disease: outcome in patients with microadenoma detected on pituitary magnetic resonance imaging. Neurosurg 2008, 109:751–759.

    Article  Google Scholar 

  45. Aghi MK: Management of recurrent and refractory Cushing disease [review]. Nat Clin Pract Endocrinol Metab 2008, 4:560–568.

    Article  PubMed  Google Scholar 

  46. Shalet S, Mukherjee A: Pharmacological treatment of hypercortisolism [review]. Curr Opin Endocrinol Diabetes Obes 2008, 15:234–238.

    PubMed  CAS  Google Scholar 

  47. Boscaro M, Ludlam WH, Atkinson B, et al.: Treatment of pituitary-dependent Cushing’s disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab 2009, 94:115–122.

    Article  PubMed  CAS  Google Scholar 

  48. Pivonello R, De Martino MC, Cappabianca P, et al.: The medical treatment of Cushing’s disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab 2009, 94:223–230.

    Article  PubMed  CAS  Google Scholar 

  49. Caturegli P, Newschaffer C, Olivi A, et al.: Autoimmune hypophysitis. Endocr Rev 2005, 26:599–614.

    Article  PubMed  CAS  Google Scholar 

  50. Freda, Pamela U: Acromegaly: medical management. In Contemporary Endocrinology: Diagnosis and Management of Pituitary Disorders. Edited by Swearingen B, Biller BMK. Totowa, NJ: Humana Press; 2008:151–169.

    Chapter  Google Scholar 

  51. Fatemi N, Dusick JR, de Paiva Neto MA, Kelly DF: The endonasal microscopic approach for pituitary adenomas and other parasellar tumors: a 10-year experience. Neurosurgery 2008, 63(4 Suppl 2):244–256.

    Article  PubMed  Google Scholar 

  52. Joshi SM, Cudlip S: Transsphenoidal surgery. Pituitary 2008, 11:353–360.

    Article  PubMed  Google Scholar 

  53. Kong DS, Lee JI, Lim do H, et al.: The efficacy of fractionated radiotherapy and stereotactic radiosurgery for pituitary adenomas: long-term results of 125 consecutive patients treated in a single institution. Cancer 2007, 110:854–860.

    Article  PubMed  Google Scholar 

  54. Molitch ME, Grossman AB: Pituitary radiotherapy. Pituitary 2009, 12:1–2.

    Article  PubMed  Google Scholar 

  55. Brada M, Jankowska P: Radiotherapy for pituitary adenomas [review]. Endocrinol Metab Clin North Am 2008, 37:263–275, xi.

    Article  PubMed  Google Scholar 

  56. Molitch ME: Nonfunctioning pituitary tumors and pituitary incidentalomas. Endocrinol Metab Clin North Am 2008, 37:151–171, xi.

    Article  PubMed  Google Scholar 

  57. Asa SL: Practical pituitary pathology: What does the pathologist need to know? Arch Pathol Lab Med 2008, 132:1231–1240.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Johns Hopkins School of Endocrinology and Metabolism, 1830 East Monument Street, Suite 333, Baltimore, MD, 21287, USA

    Roberto Salvatori

Authors
  1. Nestoras Mathioudakis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roberto Salvatori
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Roberto Salvatori.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mathioudakis, N., Salvatori, R. Pituitary tumors. Curr Treat Options Neurol 11, 287–296 (2009). https://doi.org/10.1007/s11940-009-0032-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11940-009-0032-6

Keywords

Search

Navigation